28:1332 Diversity-Product Liability
Third-party payors in a class action alleging GlaxoSmithKline LLC misrepresented the safety of its Avandia diabetes drugs told a Pennsylvania federal judge on Thursday that the pharmaceutical company is distorting what they’re actually claiming.
United Benefit Fund, one of four payors who filed a class action alleging GlaxoSmithKline LLC misrepresented the safety of its Avandia diabetes drugs, took one for the team Friday and asked a Pennsylvania federal court to kill its own claims for a faster resolution.
A Pennsylvania federal judge has ruled that the lead plaintiff in a proposed class action rolled into multidistrict litigation covering claims that GlaxoSmithKline LLC concealed dangerous side effects of its diabetes drug Avandia failed to show that she was harmed in any way.
GlaxoSmithKline LLC on Monday asked the Third Circuit to toss racketeering claims in three class actions accusing the drugmaker of hiding heart disease risks associated with the diabetes drug Avandia, arguing the plaintiffs haven’t alleged a clearly identifiable injury.
Girardi Keese said Tuesday that it will appeal to the Third Circuit to fight a May order requiring GlaxoSmithKline to hold back 7 percent of the gross recovery from all Girardi cases in the sprawling Avandia product liability multidistrict litigation.
A Pennsylvania district judge dismissed 115 out of 117 cases that GlaxoSmithKline LLC argued were outside the statute of limitations in the multidistrict litigation over injuries caused by diabetes drug Avandia, ruling Friday that the cases were clearly untimely.
A Pennsylvania federal judge on Tuesday denied GlaxoSmithKline PLC's bid to partially dismiss false advertising claims brought by Santa Clara County, Calif., over GSK's diabetes medication Avandia, rejecting its argument that the claims must be based on false advertising displayed within the county.
GlaxoSmithKline LLC failed Wednesday to escape a trio of racketeering class actions in Pennsylvania federal court alleging its concealment of heart risks associated with the diabetes drug Avandia conned health benefit payors into covering pricey prescriptions.
Plaintiffs' attorneys on Thursday filed a plan in Pennsylvania federal court to split $143 million to resolve a fee dispute in what could be a $2.3 billion settlement in a massive multidistrict litigation over GlaxoSmithKline PLC's alleged failure to warn consumers about health risks related to its diabetes drug Avandia.
A group of plaintiffs urged a Pennsylvania federal judge on Thursday to endorse the transfer of their suits claiming the GlaxoSmithKline PLC diabetes drug Avandia caused heart attacks from multidistrict litigation to the courts where they were filed, arguing the MDL had run its course.